GMG Product Commercialisation Process, Corporate Growth & Channel Strategy
BRISBANE, AUS, Sep 6, 2023 – (ACN Newswire) – Graphene Manufacturing Group Ltd. (TSXV: GMG)…
BRISBANE, AUS, Sep 6, 2023 – (ACN Newswire) – Graphene Manufacturing Group Ltd. (TSXV: GMG)…
LOS ALTOS, CA, Sep 6, 2023 – (ACN Newswire) – UroViu Corporation, the developer of…
Brisbane, Queensland, Australia–(ACN Newswire – September 6, 2023) – Graphene Manufacturing Group Ltd. (TSXV: GMG)…
IT leaders are transitioning from single vendor, “one-size fits all” traditional ERP model to optimize…
SOMERVILLE, Mass. & SAN MATEO, Calif.–(BUSINESS WIRE)–Naveo Credit Union, a full service, not-for-profit credit union…
The ExecFactor® initiative will offer digital solutions and business workflow design services DETROIT–(BUSINESS WIRE)–Leading middle-market…
Headlined by GTM Roundtable with ZoomInfo CEO Henry Schuck and Executives from Snowflake and Bain,…
B2b and b2c markets include AV, gaming and home automation NEW YORK, September 6, 2023 – Technology public…
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI…
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI…
SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical…
SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical…
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology…
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology…
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or…
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or…
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the…
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the…
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of…
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of…